

Table SI. The cut-off values of serum VEGF levels for the overall survival and recurrence-free survival.

Figure	Cut-off value (pg/ml)	Sensitivity (%)	Specificity (%)	AUC area	95%CI	P- value
4A	137	78.35	44.00	0.554	0.450-0.659	0.306
4B	161.75	74.23	58.00	0.630	0.530-0.731	0.011
5A	102	31.58	87.07	0.564	0.468-0.661	0.193
5B	147	73.68	41.38	0.517	0.424-0.610	0.726
5C	232	76.09	54.55	0.517	0.311-0.723	0.873
5D	992	89.13	27.27	0.518	0.323-0.713	0.858
5E	992	89.13	27.27	0.518	0.323-0.713	0.858
5F	138	87.88	62.50	0.760	0.551-0.968	0.015

Table SII. Relation of pre-treatment serum VEGF to clinicopathological characteristics of 173 patients with locally advanced resectable esophageal squamous cell carcinoma.

Group	n	Serum VEGF, mean $\pm$ SD	P-value
Gender			0.969
Male	147	250.78 $\pm$ 183.41	
Female	26	252.27 $\pm$ 148.09	
Age, years			0.608
≤ 60	88	262.07 $\pm$ 170.68	
60-70	62	246.16 $\pm$ 175.46	
≥ 70	23	221.74 $\pm$ 125.35	
TNM staging			0.835
III	62	247.21 $\pm$ 161.72	
IV	111	253.13 $\pm$ 187.40	
Recurrence			<0.001
Yes	57	488.65 $\pm$ 427.55	
No	116	256.45 $\pm$ 168.88	
Metastasis ¹			0.485
Yes	144	246.75 $\pm$ 180.98	
No	29	272.14 $\pm$ 164.78	
Metastasis mode			0.024 ²
Lymph node metastasis	84	256.88 $\pm$ 180.96	
Distal metastasis	13	139.46 $\pm$ 83.76	
Both	47	258.32 $\pm$ 193.22	

¹Metastasis including lymph node metastasis and distal metastasis. ²Comparison between lymph node metastasis and distal metastasis. VEGF, vascular endothelial growth factor.

Table SIII. Patient characteristics in relation to recurrent and non-recurrent patients with locally advanced resectable esophageal squamous cell carcinoma.

Characteristic	Total, n (%)	Without recurrence group, n (%)	With recurrence group, n (%)	P-value
All	173	116	57	
Age, years				0.047
≤60	88 (50.9)	53 (45.7)	35 (61.4)	
60-70	62 (35.8)	43 (37.1)	19 (33.3)	
≥70	23 (13.3)	20 (17.2)	3 (5.3)	
Sex				0.245
Male	147 (85.0)	96 (82.8)	51 (89.5)	
Female	26 (15.0)	20 (17.2)	6 (10.5)	
Stage				0.386
III	62 (35.8)	39 (33.6)	23 (40.4)	
IV	111 (64.2)	77 (66.4)	34 (59.6)	
Metastasis				0.810
Yes	144 (83.2)	96 (82.8)	48 (84.2)	
No	29 (16.8)	20 (17.2)	9 (15.8)	
Metastasis mode				1.000 ¹
Lymph node metastasis	84 (48.6)	55 (47.4)	29 (50.9)	
Distal metastasis	13 (7.5)	9 (7.8)	4 (7.0)	
Both	47 (27.2)	32 (27.6)	15 (26.3)	
Treatment ²				0.146
Chemo	116 (67.1)	82 (70.7)	34 (59.6)	
Chemo + Radio	57 (32.9)	34 (29.3)	23 (40.4)	
Evaluation ³				0.283
Improved	127 (93.4)	83 (95.4)	44 (89.8)	
Not healed	9 (6.6)	4 (4.6)	5 (10.2)	

¹Comparison between lymph node metastasis and distal metastasis. ²Chemo, patients received at least four cycles of chemotherapy; Chemo + Radio, patients received concurrent radiotherapy at the first cycle of chemotherapy. ³According to the clinical treatment effect.